As a rare cancer with a rising incidence rate in the United States, little is known about the risk factors and etiologies of appendix cancer. Additionally, in the absence of prognostic and predictive biomarkers and new therapeutic targets specific to appendiceal cancer, therapeutic advances in this malignancy remain very limited.
The study of appendix cancer patients in diverse cohorts with comprehensive clinical and individual-level information in the NCI Cohort Consortium is necessary to determine the extent to which access to healthcare, health behaviors, and potential environmental exposures may contribute to differences in disease risk and outcomes among patients with appendix cancer.
The overarching objective of the Appendiceal Cancer Consortium (APPECC) is to understand risk factors, etiologies, and prognostic factors of appendix cancer and utilize this knowledge to reverse the increasing disease burden as well as inform clinical, molecular, and population-level features that contribute to appendix cancer disparities.
To establish project feasibility for APPECC, a pilot study has been generously funded in 2022 by the Appendix Cancer Pseudomyxoma Peritonei (ACPMP) Research Foundation: